Defining a Target Population to Effectively Test a Neuroprotective Drug

Area of Science:

• Neuroscience
• Neurology
• Radiology

Background:

• Acute ischemic stroke treatment aims to improve patient outcomes.
• Neuroprotective drugs are being investigated to enhance recovery.
• Identifying patient subgroups likely to benefit is essential for trial efficacy.

Purpose of the Study:

• To identify acute ischemic stroke patients most likely to benefit from neuroprotective drugs.
• To evaluate if different patient selection strategies improve the detection of treatment effects.

Main Methods:

• Analysis of 627 acute ischemic stroke patients undergoing endovascular treatment.
• Association between final infarct volume (FIV) and National Institutes of Health Stroke Scale (NIHSS) at discharge/day 5.
• Use of computed tomography (CT) perfusion for baseline imaging criteria and patient selection.

Main Results:

• A quadratic function best described the relationship between FIV and 5-day NIHSS.
• Excluding patients with predicted larger FIV maximized treatment effect in absolute FIV reduction models.
• Excluding patients with expected excellent outcomes increased treatment effect in relative FIV reduction models.

Conclusions:

• Excellent outcomes or large infarcts in patient cohorts can dilute treatment effects in neuroprotection trials.
• CT perfusion imaging can aid in selecting patients based on expected drug effect profiles.
• Optimized patient selection is key for demonstrating the efficacy of neuroprotective agents.